MedTrace Logo

Safety of Ertapenem in Beta-lactam Allergic Patients.

NCT01159379 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2011-01-05

No results posted yet for this study

Summary

The purpose of this study is to assess cross-reactivity and tolerability of ertapenem in patients with IgE-mediated allergy to at least one beta-lactam molecule.

Conditions

  • IgE-Mediated Hypersensitivity
  • Allergy

Interventions

DRUG

ertapenem

intravenous, 1 gram, once

Sponsors & Collaborators

Principal Investigators

  • Domenico Schiavino, MD · Allergy Department, Catholic University of the Sacred Heart

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2011-09-30
Completion
2011-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01159379 on ClinicalTrials.gov